Updated Aug 28, 9:10 PM · 60 sources analyzed
Key Takeaways
Today's sources are dominated by registry status changes — no efficacy data released; clinical readouts are informational only.
BioNTech's RNA malaria vaccine trial completion sets up a near-term immunogenicity readout that could validate mRNA beyond infectious disease.
AbbVie's termination of the emraclidine schizophrenia extension study effectively closes the M4-selective muscarinic chapter for that asset.
🏆 Winner
BioNTech — completion of the first mRNA malaria vaccine Phase 1/2a positions the company for a potentially differentiated data readout in an unmet-need infectious disease with no approved RNA vaccine
📉 Loser
AbbVie — termination of the emraclidine long-term safety study signals the end of the road for its M4-selective schizophrenia asset acquired via the costly Cerevel deal
🔭 Watch Next
The most consequential near-term event visible in today's sources is BioNTech's pending release of BNT165e immunogenicity and efficacy data from its completed mRNA malaria Phase 1/2a study, expected at ASTMH or a comparable infectious disease congress in late 2026.
BioNTech RNA Malaria Vaccine Phase 1/2 Trial Completes
BioNTech's investigational mRNA-based malaria vaccine (BNT165e) completed a Phase 1/2a dose-escalation study evaluating safety, tolerability, immunogenicity, and efficacy against P. falciparum malaria in healthy volunteers, per a ClinicalTrials.gov status update. The trial marks a significant step in applying mRNA vaccine technology — proven in COVID-19 — to one of the world's highest-burden infectious diseases, though no efficacy or safety data have been released publicly. If BNT165e shows meaningful protection, it would enter a field where no licensed mRNA vaccine yet exists, intensifying competition with established adjuvanted protein-subunit approaches from GSK and Oxford-Serum.
ClinicalTrials.gov ↗CD28-Selective Small Molecule Restrains Pathogenic T Cells in IBD Without Blocking CTLA-4
Researchers used a NanoBiT split-luciferase screening platform to identify and optimize a small molecule that selectively inhibits CD28 costimulation (a signal T cells need to become fully activated) without disrupting CTLA-4 signaling, and showed it suppresses pathogenic T-cell responses in inflammatory bowel disease models.
Why it matters
If the selectivity and in vivo activity of this compound hold up in further preclinical and eventual early-phase clinical testing, this work could seed a new class of oral immunomodulators for IBD — a market currently dominated by biologics including anti-TNFs, anti-integrins, and IL-23 inhibitors. Pharma BD teams working on IBD pipeline gaps should track this group closely as it moves toward IND-enabling studies.
What to watch
Watch for the research group to publish peer-reviewed data in a journal and announce IND-enabling toxicology studies, which would indicate commercial interest and a timeline toward first-in-human trials.
Novartis Pharmaceuticals
Pelacarsen (TQJ230) in Cardiovascular disease with elevated lipoprotein(a)
This pivotal Phase 3 trial (Lp(a) HORIZON) evaluating pelacarsen for reduction of major cardiovascular events in patients with established CVD and elevated Lp(a) has been marked Completed on ClinicalTrials.gov. Detailed efficacy data have not yet been released in this registry update.
Why it matters
The trial completion status alone tells investors little — what matters is whether Novartis releases topline outcomes data showing a meaningful reduction in MACE (major adverse cardiovascular events, such as heart attack and stroke). The Lp(a) space also has competition from Silence Therapeutics' zerlasiran and Ionis' olpasiran partnerships, so the timing and magnitude of pelacarsen's results will set the commercial ceiling for the entire class.
What to watch
Watch for Novartis to announce topline MACE data from the Lp(a) HORIZON trial, expected to be presented at a major cardiology congress such as AHA or ESC; any delay in data disclosure will raise questions about the direction of results.
Bristol-Myers Squibb
Mavacamten in Non-obstructive hypertrophic cardiomyopathy (HCM)
A Phase 3 study of mavacamten in symptomatic non-obstructive HCM (a form of the disease where the heart's outflow tract is not mechanically blocked) has been marked Completed on ClinicalTrials.gov. No efficacy or safety data are included in this registry update.
Why it matters
The non-obstructive indication is a meaningful incremental opportunity for BMS — and a direct competitive read for Cytokinetics' aficamten, which is also pursuing HCM broadly. Whether this trial was powered to show symptom improvement or a functional endpoint will determine how regulators and payers receive any NDA expansion filing.
What to watch
Watch for BMS to present full efficacy data from this non-obstructive HCM Phase 3 at a cardiology meeting such as ACC or AHA, and for any subsequent sNDA (supplemental approval application) filing timeline announcement.
Kallyope Inc.
Elismetrep (K-304) in Acute migraine
A Phase 2b double-blind, randomized, placebo-controlled study of elismetrep for acute treatment of migraine has been marked Completed on ClinicalTrials.gov. No efficacy or safety data are included in this registry update.
Why it matters
Kallyope is a private company backed by a strong VC syndicate, so the completion of this Phase 2b trial is a potential inflection point for Series C fundraising or partnership conversations. The migraine acute-treatment field is crowded with approved gepants, but a clean efficacy and tolerability profile for a novel mechanism could attract large-pharma licensing interest quickly.
What to watch
Watch for Kallyope to release topline Phase 2b data at a neurology conference such as AHS or IHC, and for any signals of a partnership or financing round in the months following a data readout.
This pivotal Phase 3 trial (Lp(a) HORIZON) evaluating pelacarsen for reduction of major cardiovascular events in patients with established CVD and elevated Lp(a) has been marked Completed on ClinicalTrials.gov. Detailed efficacy data have not yet been released in this registry update.
Why it matters
Pelacarsen is one of the most-watched cardiovascular outcomes trials in recent years; Lp(a) is a genetically elevated lipid fraction linked to atherosclerotic risk that has no approved therapy, representing a potential multi-billion-dollar market if the drug shows event reduction.
Analysis
The trial completion status alone tells investors little — what matters is whether Novartis releases topline outcomes data showing a meaningful reduction in MACE (major adverse cardiovascular events, such as heart attack and stroke). The Lp(a) space also has competition from Silence Therapeutics' zerlasiran and Ionis' olpasiran partnerships, so the timing and magnitude of pelacarsen's results will set the commercial ceiling for the entire class.
What to watch
Watch for Novartis to announce topline MACE data from the Lp(a) HORIZON trial, expected to be presented at a major cardiology congress such as AHA or ESC; any delay in data disclosure will raise questions about the direction of results.
A Phase 3 study of mavacamten in symptomatic non-obstructive HCM (a form of the disease where the heart's outflow tract is not mechanically blocked) has been marked Completed on ClinicalTrials.gov. No efficacy or safety data are included in this registry update.
Why it matters
Mavacamten (Camzyos) is already approved for obstructive HCM; a positive result in the non-obstructive form would expand the addressable patient population substantially and could set terms for the entire cardiac myosin inhibitor class.
Analysis
The non-obstructive indication is a meaningful incremental opportunity for BMS — and a direct competitive read for Cytokinetics' aficamten, which is also pursuing HCM broadly. Whether this trial was powered to show symptom improvement or a functional endpoint will determine how regulators and payers receive any NDA expansion filing.
What to watch
Watch for BMS to present full efficacy data from this non-obstructive HCM Phase 3 at a cardiology meeting such as ACC or AHA, and for any subsequent sNDA (supplemental approval application) filing timeline announcement.
A Phase 2b double-blind, randomized, placebo-controlled study of elismetrep for acute treatment of migraine has been marked Completed on ClinicalTrials.gov. No efficacy or safety data are included in this registry update.
Why it matters
Elismetrep represents a gut-brain axis mechanism targeting the 5-HT4 receptor — a mechanistically distinct approach from the dominant gepant and triptan classes — and a positive Phase 2b result would validate a new pathway in a large, commercially active migraine market.
Analysis
Kallyope is a private company backed by a strong VC syndicate, so the completion of this Phase 2b trial is a potential inflection point for Series C fundraising or partnership conversations. The migraine acute-treatment field is crowded with approved gepants, but a clean efficacy and tolerability profile for a novel mechanism could attract large-pharma licensing interest quickly.
What to watch
Watch for Kallyope to release topline Phase 2b data at a neurology conference such as AHS or IHC, and for any signals of a partnership or financing round in the months following a data readout.
A Phase 1/2a randomized, dose-escalation study of BNT165e — an investigational RNA-based vaccine for prevention of P. falciparum malaria in healthy volunteers — has been marked Completed on ClinicalTrials.gov. Detailed immunogenicity and efficacy data have not yet been released in this registry update.
Why it matters
If mRNA technology can generate durable malaria protection, it would be the first RNA vaccine approved for a parasitic disease and could redefine the global malaria vaccine competitive landscape currently dominated by GSK's Mosquirix and Oxford's R21.
Analysis
BioNTech has staked significant pipeline capital on mRNA infectious disease vaccines beyond COVID-19; this trial completion sets up a near-term data readout that will be a meaningful test of whether BNT165e's immunogenicity translates to meaningful protective efficacy against controlled human malaria infection. The absence of disclosed data at completion is not unusual for academic-era controlled infection studies, but investors should expect results within one to two conference cycles.
What to watch
Watch for BioNTech to present BNT165e immunogenicity and challenge-model efficacy data at an infectious disease or vaccinology meeting such as ASTMH or CROI in late 2026, which would determine whether Phase 2b field-efficacy studies are warranted.
A Phase 2b/3 study of linsitinib — an oral small-molecule IGF-1R inhibitor (a drug that blocks a growth-factor receptor linked to the inflammation driving thyroid eye disease) — in moderate-to-severe TED has been marked Completed on ClinicalTrials.gov. No proptosis response rate, clinical activity score, or other efficacy data are included in this registry update.
Why it matters
Thyroid eye disease has one approved biologic (Amgen/Horizon's teprotumumab, an IV infusion), and an effective oral alternative would command strong commercial and patient-preference advantages in a rare disease with approximately 20,000 active moderate-to-severe U.S. patients.
Analysis
Linsitinib's oral route of administration is its primary differentiator against teprotumumab, but the drug must demonstrate comparable proptosis reduction — the FDA-recognized primary endpoint — to be commercially relevant. The trial completion without public data release suggests a formal readout is imminent, and the result will either validate IGF-1R small-molecule inhibition as a category or close the door on this approach.
What to watch
Watch for Sling Therapeutics to announce topline proptosis response data in the coming months, which would determine whether the company proceeds to an NDA filing or pursues a larger pharma partnership to fund a Phase 3 confirmatory study.
Juul Labs
Juul Labs received FDA authorization to market an updated e-cigarette device incorporating optional age-verification technology, per STAT News.
Why it matters
This is the first FDA-authorized vaping device with an integrated age-gating system, setting a potential regulatory precedent that other e-cigarette manufacturers may be required or incentivized to follow as the agency continues to tighten youth access controls.
Analysis
While not a pharma or biotech event, this FDA action is a meaningful signal for public health-focused investors and tobacco-harm-reduction players: the agency is willing to authorize next-generation consumer nicotine products if they incorporate meaningful safeguards, which could accelerate the regulatory pathway for other reduced-risk nicotine technologies and pharmaceutical nicotine replacement products.
What to watch
Watch for FDA to issue broader guidance on age-verification requirements for e-cigarette manufacturers and for competing device makers such as NJOY (owned by Altria) to file for similar authorizations incorporating comparable technology.
CD28-Selective Small Molecule Restrains Pathogenic T Cells in IBD Without Blocking CTLA-4
Researchers used a NanoBiT split-luciferase screening platform to identify and optimize a small molecule that selectively inhibits CD28 costimulation (a signal T cells need to become fully activated) without disrupting CTLA-4 signaling, and showed it suppresses pathogenic T-cell responses in inflammatory bowel disease models.
Why it matters
Current B7-directed biologics (such as abatacept) block both CD28 and CTLA-4 pathways, limiting regulatory T-cell function; a CD28-selective oral inhibitor could achieve anti-inflammatory efficacy with a cleaner immunological profile and a significant formulation advantage over IV biologics.
Analysis
If the selectivity and in vivo activity of this compound hold up in further preclinical and eventual early-phase clinical testing, this work could seed a new class of oral immunomodulators for IBD — a market currently dominated by biologics including anti-TNFs, anti-integrins, and IL-23 inhibitors. Pharma BD teams working on IBD pipeline gaps should track this group closely as it moves toward IND-enabling studies.
What to watch
Watch for the research group to publish peer-reviewed data in a journal and announce IND-enabling toxicology studies, which would indicate commercial interest and a timeline toward first-in-human trials.
Amgen's Daxdilimab Phase 2 in Dermatomyositis and Anti-Synthetase Myositis Completes
A Phase 2 proof-of-concept study of daxdilimab — an anti-ILT7 antibody (a receptor that dampens overactive plasmacytoid dendritic cells, which drive type I interferon-mediated autoimmune damage) — in dermatomyositis and anti-synthetase inflammatory myositis has been marked Completed on ClinicalTrials.gov, with no efficacy data yet disclosed.
Why it matters
Dermatomyositis and anti-synthetase syndrome are rare, type I interferon-driven diseases with no approved therapies beyond off-label immunosuppression; a positive signal for ILT7 blockade would open a mechanistically validated pathway for this underserved population.
Analysis
Daxdilimab is also in Phase 2 for systemic lupus, giving Amgen a read on ILT7 biology across multiple interferon-driven diseases simultaneously; success in the myositis proof-of-concept would strengthen the broader platform thesis and inform optimal patient-selection biomarkers for the lupus program.
What to watch
Watch for Amgen to present proof-of-concept efficacy data — particularly the Total Improvement Score (TIS) at Week 24 — at ACR or EULAR in the next twelve months, which will determine whether daxdilimab advances to Phase 3 in myositis.
AbbVie Terminates Long-Term Safety Study of Emraclidine in Schizophrenia
AbbVie has terminated a Phase 2 long-term safety and tolerability study of emraclidine (CVL-231), an M4-selective muscarinic agonist for schizophrenia, per a ClinicalTrials.gov status update, with no safety or outcome data disclosed.
Why it matters
Emraclidine's termination in this extension study adds to prior Phase 2 failures in the muscarinic agonist class and raises further questions about whether the receptor selectivity profile (M4 versus M1/M4 dual agonism) is sufficient to produce antipsychotic efficacy without the tolerability problems seen with earlier agents.
Analysis
AbbVie acquired CVL-231 as part of its Cerevel Therapeutics acquisition; the termination of this extension study signals that the asset is unlikely to advance in schizophrenia, which will push investor attention toward AbbVie's other Cerevel-derived assets and raises the broader question of whether M4-selective agonism is the right pharmacological strategy. Competitors in the muscarinic schizophrenia space — including Karuna/BMS's KarXT (xanomeline-trospium) — now face less near-term differentiation pressure from AbbVie.
What to watch
Watch for AbbVie to formally disclose the reason for termination — whether safety-driven or strategic — and for any pipeline reassessment announcement regarding the broader Cerevel neuroscience portfolio in the next quarterly earnings call.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.